SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), ...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...

KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital reveals how multiple myeloma, a form of ...

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer. Darzalex Faspro is the ...

Multiple myeloma is a relatively uncommon cancer of plasma cells, where excessive proliferation of these malignant cells within the bone marrow leads to abnormal antibody production. The disease ...

TORONTO -- For some patients with multiple myeloma and their physicians, progression-free survival (PFS) is just as important as overall survival (OS), according to results from a cross-sectional ...

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...